6% Hetastarch In 0.9% Sodium Chloride
Generic Name: 6% hetastarch in 0.9% sodium chloride
Brand Names:
6% Hetastarch In 0.9% Sodium Chloride
11 DESCRIPTION 6% Hetastarch in 0.9% Sodium Chloride Injection is a sterile, nonpyrogenic solution for intravenous administration. Each 100 mL contains: Hetastarch............................................................................ 6 g Sodium Chloride, USP........................................................ 0.9 g Water for Injection, USP.....................................................
Overview
11 DESCRIPTION 6% Hetastarch in 0.9% Sodium Chloride Injection is a sterile, nonpyrogenic solution for intravenous administration. Each 100 mL contains: Hetastarch............................................................................ 6 g Sodium Chloride, USP........................................................ 0.9 g Water for Injection, USP.....................................................
Uses
1 INDICATIONS AND USAGE 6% Hetastarch in 0.9% Sodium Chloride Injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired. It is not a substitute for blood or plasma. The adjunctive use of 6% Hetastarch in 0.9% Sodium Chloride Injection in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means.
Dosage
2 DOSAGE & ADMINISTRATION Dosage for Acute Use in Plasma Volume Expansion 6% Hetastarch in 0.9% Sodium Chloride Injection is administered by intravenous infusion only. Total dosage and rate of infusion depend upon the amount of blood or plasma lost and the resultant hemoconcentration. 2.1 Adults The amount usually administered is 500 to 1000 mL. Doses of more than 1500 mL per day for the typical 70 kg patient (approximately 20 mL per kg of body weight) are usually not required. Higher doses have been reported in postoperative and trauma patients where severe blood loss has occurred [see WARNINGS AND PRECAUTIONS (5 )].
Side Effects
6 ADVERSE REACTIONS The serious adverse events reported in clinical trials are increased mortality and renal replacement therapy renal in critically ill patients. Most common adverse reactions are hypersensitivity, coagulopathy, hemodilution, circulatory overload and metabolic acidosis. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Three randomized controlled trials (RCTs) followed critically ill adult patients treated with different HES products for 90 days.
Interactions
7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system. • The safety and compatibility of other additives have not been established.
Warnings
BOXED WARNING BOXED WARNING 5 WARNINGS AND PRECAUTIONS 5.1 Renal Dysfunction • Avoid use in patients with pre-existing renal dysfunction • Discontinue use of 6% Hetastarch in 0.9% Sodium Chloride Injection at the first sign of renal injury • Continue to monitor renal function in hospitalized patients for at least 90 days as use of RRT has been reported up to 90 days after administration of HES products, including 6% Hetastarch in 0.9% Sodium Chloride Injection 5.2 Coagulopathy • 6% Hetastarch in 0.9% Sodium Chloride Injection is not recommended for use as a cardiac bypass pump prime, while the patient is on cardiopulmonary bypass, or in the immediate period after the pump has been discontinued because of the risk of increasing coagulation abnormalities and bleeding in patients whose coagulation status is already impa... 4 CONTRAINDICATIONS Do not use hydroxyethyl starch (HES) products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (RRT).
Storage
16 HOW SUPPLIED/STORAGE AND HANDLING 6% HETASTARCH IN 0.9% SODIUM CHLORIDE is supplied in the following dosage forms. NDC 51662-1317-1 6% HETASTARCH IN 0.9% SODIUM CHLORIDE INJECTION 500mL BAG NDC 51662-1317-2 6% HETASTARCH IN 0.9% SODIUM CHLORIDE INJECTION 500mL BAG supplied in a Case NDC 51662-1317-3 6% HETASTARCH IN 0.9% SODIUM CHLORIDE INJECTION 500mL BAG, 12 Containers of 51662-1317-2 in a Ca...
Frequently Asked Questions
What is 6% Hetastarch In 0.9% Sodium Chloride used for?▼
1 INDICATIONS AND USAGE 6% Hetastarch in 0.9% Sodium Chloride Injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired. It is not a substitute for blood or plasma. The adjunctive use of 6% Hetastarch in 0.9% Sodium Chloride Injection in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means.
What are the side effects of 6% Hetastarch In 0.9% Sodium Chloride?▼
6 ADVERSE REACTIONS The serious adverse events reported in clinical trials are increased mortality and renal replacement therapy renal in critically ill patients. Most common adverse reactions are hypersensitivity, coagulopathy, hemodilution, circulatory overload and metabolic acidosis. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Three randomized controlled trials (RCTs) followed critically ill adult patients treated with different HES products for 90 days.
What are the important warnings for 6% Hetastarch In 0.9% Sodium Chloride?▼
BOXED WARNING BOXED WARNING 5 WARNINGS AND PRECAUTIONS 5.1 Renal Dysfunction • Avoid use in patients with pre-existing renal dysfunction • Discontinue use of 6% Hetastarch in 0.9% Sodium Chloride Injection at the first sign of renal injury • Continue to monitor renal function in hospitalized patients for at least 90 days as use of RRT has been reported up to 90 days after administration of HES products, including 6% Hetastarch in 0.9% Sodium Chloride Injection 5.2 Coagulopathy • 6% Hetastarch in 0.9% Sodium Chloride Injection is not recommended for use as a cardiac bypass pump prime, while the patient is on cardiopulmonary bypass, or in the immediate period after the pump has been discontinued because of the risk of increasing coagulation abnormalities and bleeding in patients whose coagulation status is already impa... 4 CONTRAINDICATIONS Do not use hydroxyethyl starch (HES) products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (RRT).
Related Medications
Allium Cepa, Allium Sativum, Alpha-lipoicum Acidum, Alumina, Arsenicum Metallicum, Berberis Vulgaris, Cadmium Metallicum, Carduus Marianus, Cetraria Islandica, Cuprum Metallicum, Cysteinum, Glycyrrhiza Glabra, Hepar Suis, Lappa Major, Lycopodium Clavatum, Mercurius Solubilis, Nux Vomica, Plantago Major, Plumbum Metallicum, Pyridoxinum Hydrochloricum, Selenium Metallicum, Stillingia Sylvatica, Thyroidinum, Trifolium Pratense, Zingiber Officinale
allium cepa, allium sativum, alpha-lipoicum acidum, alumina, arsenicum metallicum, berberis vulgaris, cadmium metallicum, carduus marianus, cetraria islandica, cuprum metallicum, cysteinum, glycyrrhiza glabra, hepar suis, lappa major, lycopodium clavatum, mercurius solubilis, nux vomica, plantago major, plumbum metallicum, pyridoxinum hydrochloricum, selenium metallicum, stillingia sylvatica, thyroidinum, trifolium pratense, zingiber officinale
Copper-containing Intrauterine Device [EPC]
Purpose Temporary relief of metallic taste, irritability, difficulty concentrating.
Hypromellose, Tetrahydrozoline Hydrochloride
hypromellose, tetrahydrozoline hydrochloride
Purpose Hypromellose - Lubricant Tetrahydrozoline hydrochloride - Redness reliever
Diphenhydramine Hydrochloride, Pramoxine Hydrochloride
diphenhydramine hydrochloride, pramoxine hydrochloride
Purposes Topical analgesic Topical analgesic
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.